Edoxaban: an update on the new oral direct factor Xa inhibitor. - Test2 - elhamkhani - TriplyDB

Edoxaban: an update on the new oral direct factor Xa inhibitor.

Edoxaban: an update on the new oral direct factor Xa inhibitor.

http://www.wikidata.org/entity/Q33935409

about

Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome Edoxaban in venous thromboembolism and stroke prevention: an appraisal The evolution of anticoagulant therapy Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence New Oral Anticoagulants in Nonvalvular Atrial Fibrillation Pharmacology of anticoagulants used in the treatment of venous thromboembolism Edoxaban.Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.Edoxaban: a review in nonvalvular atrial fibrillation.Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.Drug-drug interactions of non-vitamin K oral anticoagulants.Drug Interactions of Direct-Acting Oral Anticoagulants.Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke.Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.New Oral Anticoagulants and Their Reversal Agents.Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.Reversal of direct oral anticoagulants.The role of new oral anticoagulants in orthopaedics: an update of recent evidence.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction.A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.New Direct Oral Anticoagulants (DOAC) and Their Use Today.

P2860

Q24185813-C530A394-0D0D-4873-95B3-7A0EA0B28509 Q26751263-CB257406-DB39-4918-AEA3-DEF87EF61072 Q26771859-A6CCD6A0-3CE0-4453-A9D7-781B357B4F15 Q26782483-A6DF77F7-A03A-43B8-8498-6D08537BCB90 Q28066141-11DD3332-B4BC-4255-A660-885F52752588 Q28078967-F8C8F9FF-6E85-41FD-BA99-A9DEDBE35D8C Q36109959-4ED897D1-EA24-4C0F-9777-80C5BA1F7BD4 Q37699699-4F519C8B-D444-4A1C-8A1D-A1D8B0096E76 Q38525918-93461084-CA26-4772-B8CB-C98D6FD59809 Q38586582-5F937199-8A0F-4B95-BAF7-A548BDD7A303 Q38627495-140A6C61-0F5E-4C8A-98EE-3BCFAEFB95CA Q38687974-79B57F7E-F686-42F5-A0FF-7188450CA532 Q38750444-4470FB3D-E352-404D-B7A3-310E9C5C9E6A Q38819152-E7109928-6371-435C-85A4-FF7C688A2384 Q38830358-AD4C4C8E-F687-4FAD-BABA-961AC1C96AF0 Q38902415-F670F032-1B81-4469-BB28-DBBFF4D5E712 Q38909618-D8A78363-EB97-4394-B9F6-4D7DE6C36E8F Q38964210-FEC5AAF7-6293-4517-875D-8E0D2EAFA8EB Q38970532-DB5E2630-9F74-40F0-B506-459B45D7D42B Q39000594-DA844316-3F91-4058-B3F3-B9E56AA75461 Q39170777-0C3285B1-28CC-4FAA-8806-8340425F5E28 Q39185541-4EA62E28-84D1-4AB8-911C-9A5785E1E898 Q39213540-B818436F-2410-4107-B664-BF23725DE4ED Q39452481-194E22B4-80ED-4E30-A92B-32A83870C82D Q40343303-B1B56289-E98B-413C-90EC-D0754731105F Q42387444-CC44498D-9416-4F2D-A392-CC505046CEB7 Q49970492-9E114935-C066-4D99-B788-30DE4AFE43D3 Q51280016-996D1DEB-1C3E-4644-B250-A2A492DA30D0 Q53531959-99BA725F-72BE-4F43-9431-08FDEBE4F195 Q54975871-E423C512-A26A-448D-A079-EDE899CFC111

P2860

Edoxaban: an update on the new oral direct factor Xa inhibitor.

http://www.wikidata.org/entity/Q33935409

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@ast

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@en

type

label

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@ast

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@en

prefLabel

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@ast

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@en

P1433

Q33935409-C65FE711-14BF-4AC5-B0A8-527EB5AF8AA8

P1476

Q33935409-ACA0F444-7EA2-4E57-9D76-F617A0319707

P2093

Q33935409-4B397117-9638-4761-A3EB-E0C6EA354293

Q33935409-B43184E5-5917-4D7A-9283-A71229E98358

P2860

Q33935409-03812C96-31E2-479D-968C-EB01A579430B

Q33935409-0660D3B5-A7F4-4CA6-A281-CAC73E1B1A68

Q33935409-0E28F0B9-F5DD-4F5A-9454-93CB65DFD0E9

Q33935409-174085DB-5DB4-4452-8410-63F16E8039D9

Q33935409-1939DB6F-927D-4BB5-8F70-E2F9D52F7CD1

Q33935409-1C18075F-3597-494F-A269-8634569D062F

Q33935409-1C30270A-8F23-4F9D-A182-90D2B66841CB

Q33935409-1DF7FDAA-C755-41AC-9518-EDB90465743A

Q33935409-2D506B36-964E-4F77-9067-3BADF97FAF63

Q33935409-30077394-F8B8-4B10-92E8-0678844A3F68

P2888

Q33935409-0CF8F732-579D-4F4C-BE7B-273EDB43BE03

P304

Q33935409-C75C39BF-A2B0-4F0E-A6D5-A34CF8CA9499

P31

Q33935409-152C6CDC-02AA-48A2-8BFF-3735386958D7

Q33935409-4365DFDB-B28A-4B65-AD00-B6376571A529

P356

Q33935409-630209D0-D854-4245-81B9-E3BBB1CC524C

P433

Q33935409-9661A439-4842-440F-B1D9-8F80E19A567D

P478

Q33935409-BD4884F4-CF7C-405D-B00D-549AC1DDF7E2

P577

Q33935409-EDDA9CA2-B820-477A-88DE-ED696A83AF5E

P5875

Q33935409-627CECE5-8AE1-4033-8309-972009163D60

P6179

Q33935409-5FE90EC6-981C-44D7-A4EF-7009B72F1D17

P698

Q33935409-FA3FCAA9-B449-4091-AE6A-E3212FCA1294

P921

Q33935409-5778044C-A584-4D4B-9FB6-747AC66C780D

Q33935409-CFE52A5F-C33E-4B7A-9D7F-46D26E7A0A5F

Q33935409-D830CED7-5443-47EE-BD7F-35EFC452B79B

P932

Q33935409-669C2CF1-7487-4B82-90AB-27D3F0FF4CB8

P356

S40265-014-0261-1

P1433

P1476

Edoxaban: an update on the new oral direct factor Xa inhibitor.

@en

P2093

A John Camm

http://www.w3.org/2001/XMLSchema#string

Henri Bounameaux

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis

Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications

Dabigatran versus warfarin in patients with atrial fibrillation

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Oral rivaroxaban for symptomatic venous thromboembolism

P2888

s40265-014-0261-1

P304

1209-1231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0261-1

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264054458

http://www.w3.org/2001/XMLSchema#string

P6179

1004100651

http://www.w3.org/2001/XMLSchema#string

P698

25034361

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

P932

4107274

http://www.w3.org/2001/XMLSchema#string